PepGen Inc. (PEPG)

The long-term investment case is severely compromised by a catastrophic multi-year decline. Despite a brief recovery in 2024, the stock has erased nearly 86% of its value over the last three years, with the most recent annual performance showing a staggering -86.4% drop. This is not a temporary correction; it is a structural implosion driven by deteriorating fundamentals, including negative earnings, negative free cash flow, and a massive 158% decline in the 200-day moving average. The balance sheet is fragile, with operating cash flows burning through capital and no dividend to provide a floor. Short-term, the situation remains precarious. While the price has staged a modest technical rebound recently, the underlying business is failing to generate value, and the recent FDA trial hold suggests ongoing regulatory hurdles that threaten the core product pipeline. The options market confirms this pessimism, with heavy put writing and minimal speculative call activity, signaling that smart money is preparing for further downside rather than chasing a bounce. The analyst consensus of 'strong buy' with a $10 target is a dangerous distraction; it ignores the reality that the market has already priced in a complete failure of the current business model. This is a value trap where the low price reflects a broken engine, not a bargain.